Singlera Genomics


Diagnostic & Medical Device
La Jolla

At the leading edge of biology and assay technology, Singlera Genomics uses a new biomarker type called ctmDNA (circulating tumor methylated DNA) to peer into the future. Targeted methylation approaches have historically not been developed due to technical hurdles. Singlera announces a unique approach, examining methylation haplotypes (adjacent methylation sites on the same contiguous strand of DNA) from cell-free DNA as a method for cancer biomarker detection. By using a highly specific and targeted methylation enrichment method, both the overall sample input requirement is lowered and the overall amount of sequencing necessary for excellent sensitivity is reduced.

DNA methylation,cancer biomarker,bioinformatics analysis